GeekWire

MARCH 8, 2022

Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, the company’s chief scientific officer. Adaptive Biotechnologies Photo). Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned. “We

Biotechnology 109

Biotechnology .Net Programming Company 109

GeekWire

OCTOBER 19, 2021

Sana Biotechnology has a new $50 million tool in its toolbox. Beam may also receive additional payments, for instance upon the achievement of development and sales milestones. Sana aims to develop therapeutics for conditions as diverse as cancer, diabetes and cardiovascular disorders. Sana CEO and president Steve Harr.

Biotechnology 121

Biotechnology System Programming Engineering 121

GeekWire

JUNE 4, 2020

Investors are betting big on the company, which announced a giant $85 million Series B investment round Thursday to help fuel late-stage development of its lead therapeutic candidate called NDX-1017. Depending on the development and approval process, Kawas said the drug could come to market within 2-to-3 years. billion in 2018.

Development 144

Development Biotechnology Research Healthcare 144

GeekWire

JULY 7, 2021

The company, a spin-out from the UW’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Icosavax is also developing shots, geared for older adults, against two viruses that cause pneumonia, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

Development 141

Development Biotechnology Pharmaceuticals .Net 141

GeekWire

FEBRUARY 15, 2022

Adaptive Biotechnologies , which develops technology to assess the immune response, posted $154.3 Progress on a collaboration with biopharma company Nykode Therapeutics to support the development of a T-cell based COVID-19 vaccine. Adaptive moved into its new headquarters in September. GeekWire Photo / Charlotte Schubert).

Biotechnology 88

Biotechnology .Net Development Study 88

GeekWire

JULY 2, 2020

OncoSenX is the spinoff of a third company, Seattle-based Oisin Biotechnologies. The researchers said they have selected the two most promising DNA sequences for further testing. Researchers at OncoSenX are using Fusogenix for cancer research on the treatment of solid tumors.

Research 145

Research Pharmaceuticals Biotechnology Development 145

GeekWire

AUGUST 12, 2024

To make a profit, yes, but also to support the development of technologies needed to sustain settlements on the Red Planet. (NASA Photo / Dominic Hart) The Mars Society says it’s making progress on launching a startup incubator in the Seattle area, with artificial intelligence and biotech as its first targets. Its long-term goal?

Biotechnology 125

Biotechnology Chemicals Artificial Intelligence Engineering 125

GeekWire

JULY 14, 2020

Adaptive Biotechnologies announced Tuesday that it will sell 8 million shares of its common stock — 6 million of its own, and 2 million from an investor — to help accelerate the company’s work.

Biotechnology 68

Biotechnology Development Microsoft Report 68

GeekWire

JUNE 11, 2024

Levitate Bio’s CEO Sam DeLuca, left, and Karen Khar, executive vice president of sales and business development. David Baker, director of the UW’s Institute for Protein Design, runs the lab that developed Rosetta and is an advocate for open-source tools. Tech companies are really good at what they do.

Software 111

Software Software Development Company 111

GeekWire

OCTOBER 10, 2023

Sana Biotechnology will reduce its workforce by 29%, the Seattle-based cell and gene therapy company revealed in a SEC filing Tuesday. Sana, which went public in 2021, said it will continue development of its manufacturing facility in Bothell, Wash. Sana previously cut 15% of its staff in November. The company said it had $325.9

Biotechnology 78

Biotechnology .Net Report Company 78

GeekWire

SEPTEMBER 21, 2021

Adaptive co-founders Harlan (left) and Chad Robins on the plaza at the new Adaptive Biotechnology headquarters. After doubling its workforce during the pandemic, Adaptive Biotechnologies finally has room to grow. The company ramped up rapidly as the pandemic accelerated, supporting the development of COVID-19 vaccines.

Biotechnology 98

Biotechnology Real Estate Analysis Research 98

GeekWire

NOVEMBER 10, 2020

Adaptive Biotechnologies CEO Chad Robins. Adaptive Biotechnologies beat expectations for its fiscal third quarter as the Seattle company continues to use its immune medicine platform in the fight against COVID-19. The company also is developing T-Detect COVID , a T-cell-based test for identifying past COVID-19 infections.

Biotechnology 71

Biotechnology Pharmaceuticals Development System 71

GeekWire

DECEMBER 20, 2021

Alexandria Real Equities , a life sciences real estate developer, has bought a 5.2-acre Alexandria bought the property from Bellevue company Pine Forest, which has been planning a large mixed-use development for the site. Alexandria is developing a life sciences hub at Seattle’s almost three-acre Mercer Mega Block.

Real Estate 116

Real Estate Development Biotechnology Journal 116

GeekWire

MAY 27, 2021

New funding: Seattle biotech startup Oisín Biotechnologies has raised a $5 million seed round. It’s currently developing preclinical therapies that target and kill damaged cells that have been biologically turned off or are “senescent” and supposed to die. Oisín Photos). Oisín has raised a total of $9.5

Development 117

Development Biotechnology Travel Study 117

GeekWire

SEPTEMBER 1, 2020

Lumen Bioscience today announced a $16 million Series B round to help support its novel approach to rapid and low-cost drug development. Lumen is led by Finrow, a former senior vice president at Adaptive Biotechnologies, and Chief Science Officer Jim Roberts , the former head of basic sciences at the Fred Hutchinson Cancer Research Institute.

Development 110

Development Biotechnology Travel Programming 110

GeekWire

AUGUST 5, 2021

Tadataka Yamada, a pioneer in drug and vaccine development who helped forge numerous biotech companies and spent six years at the Bill and Melinda Gates Foundation as head of global health, died Wednesday morning of natural causes at his home in Seattle. Tadataka “Tachi” Yamada. Twitter Photo via @TachiYamada).

Pharmaceuticals 129

Pharmaceuticals Development Biotechnology Industry 129

GeekWire

AUGUST 26, 2021

Diagnostics startup ID Genomics will accelerate its development of a quick test for variants of the COVID-19 virus with a new grant from the U.S. In addition to developing the CovNET rapid test, ID Genomics will launch a next-day sequencing service for variants within the next few weeks. National Institutes of Health.

Development 129

Development Biotechnology Small Business Analysis 129

GeekWire

JULY 29, 2021

The company, a spin-out from the University of Washington’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. Icosavax is also developing shots, geared for older adults, against two viruses that cause pneumonia, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

Biotechnology 139

Biotechnology Company Pharmaceuticals Research 139

GeekWire

NOVEMBER 19, 2020

Umoja Biopharma raised $53 million to expand development of its CAR T-cell immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. ” Umoja is one of several companies in the Seattle region developing immunotherapy-related technologies. Umoja Biopharma CEO Andy Scharenberg. Umoja Photo).

Biotechnology 142

Biotechnology Research CTO Development 142

GeekWire

AUGUST 23, 2021

Since early July alone, three of those companies went public: drug discovery platform company Absci raised $200 million, vaccine developer Icosavax raised $180 million and nervous system therapeutics company Eliem Therapeutics raised $80 million. It’s an unprecedented trend. billion, according to EndpointsNews.

Biotechnology 127

Biotechnology Company Trends Software 127

TechSpot

JULY 24, 2024

The UK Space Agency and BiologIC Technologies are partnering to develop advanced biotechnologies, including vaccines and gene therapies, for space manufacturing.

Biotechnology 104

Biotechnology Research Development 104

GeekWire

JUNE 30, 2021

based company developing technologies to accelerate the process of drug discovery, announced today that it plans to go public via an IPO. Absci aims to circumvent current processes for developing protein-based drugs, which often require manufacture in mammalian cells, a cumbersome and difficult method. Absci Photo).

Company 129

Company Biotechnology .Net Programming 129

GeekWire

JULY 27, 2020

Chad Robins, CEO of Adaptive Biotechnologies, speaks at the site of the company’s future corporate headquarters in Seattle, standing in front of the final piece of structural steel before it’s put into place. Stephen Brashear/AP Images for Adaptive Biotechnologies). Stephen Brashear/AP Images for Adaptive Biotechnologies).

Biotechnology 104

Biotechnology Real Estate Industry Microsoft 104

GeekWire

MAY 21, 2020

The 4-year-old company is developing cytokines that regulate their own activity in response to biomarkers and metabolic signals, said CEO John Mulligan. Another Seattle biotech company, Nautilus Biotechnology, announced a $76 million funding round Thursday. It is focused initially on immuno-oncology applications.

Development 86

Development Biotechnology Microsoft Applications 86

GeekWire

JANUARY 14, 2022

The Bill & Melinda Gates Foundation has committed $40 million in equity investment and $10 million in grant funding to Vir Biotechnology for the development of therapies against HIV and Malaria, Vir announced Friday. government has been buying to fight Omicron.

Biotechnology 106

Biotechnology Government Research Development 106

GeekWire

SEPTEMBER 9, 2021

Cyrus Biotechnology has several drug discovery and development partnerships and also sells Cyrus Bench, a software platform for protein engineering. Seattle-based Cyrus Biotechnology is entering a protein engineering collaboration with Boston-based Selecta Biosciences that could pull in up to $1.5 Cyrus Photo). Cyrus Photo).

Biotechnology 143

Biotechnology Engineering Software Software 143

GeekWire

OCTOBER 9, 2024

Baker and his colleagues developed an early protein design tool and made the code available through a consortium called Rosetta Commons. Baker’s research contributed to the development of the world’s first computationally designed protein medicine, a vaccine for COVID-19 pioneered by colleagues at UW Medicine.

Biotechnology 141

Biotechnology Pharmaceuticals Artificial Intelligence Research 141

GeekWire

JULY 8, 2021

Absci, which partners with other biopharma companies to identify and develop protein-based drug candidates, has its roots in Portland. Things are different now, said Alexandre, as companies such as Seagen and Adaptive Biotechnologies go public and grow in the region. Bolstering the workforce, increasing regional connections.

Biotechnology 131

Biotechnology Industry Real Estate Company 131

CTOvision

APRIL 29, 2016

CASI’s research mission is to develop and promote entirely new technologies and novel solutions to complex global challenges in health, sustainability, security and education. ASU researcher improves crop performance with new biotechnology (eurekalert.org). Find more information on ASU's usage of HDP™ to further cancer research here.

Biotechnology 150

Biotechnology Data Research Education 150

GeekWire

FEBRUARY 17, 2021

Notch Therapeutics is commercializing technologies developed in the labs of Juan-Carlos Zúñiga-Pflücker, left, chair of Notch’s scientific advisory board, and Chief Scientific Officer Peter Zandstra. The biotech company was founded in 2018 and is developing stem cell-derived immunotherapies for cancer. Notch Photo).

Biotechnology 122

Biotechnology Pharmaceuticals Research Development 122

GeekWire

DECEMBER 9, 2024

But the University of Washington professor is surely itching to get back to his lab on campus in Seattle, where he works with students and fellow researchers on the future of protein design, a fast-moving field using state-of-the-art technology to develop new therapeutics, vaccines, biosensors, materials and more. AstraZeneca paid $1.1

Biotechnology 110

Biotechnology Pharmaceuticals Chemicals Research 110

GeekWire

DECEMBER 6, 2021

The news: Seattle-based protein engineering company Cyrus Biotechnology has raised $18 million and acquired Orthogonal Biologics , a spinout from the University of Illinois at Urbana Champaign, which is developing a COVID-19 therapeutic. Cyrus CEO Lucas Nivon. Cyrus Photo).

Software 99

Software Software Development Mobile 99

GeekWire

FEBRUARY 26, 2021

This was a first-of-its kind diagnostic tool from Seattle-based Adaptive Biotechnologies , a company that develops technology to sequence the human immune system for the diagnosis and treatment of disease. Adaptive Biotechnologies’ new test, called T-Detect COVID , was developed in partnership with Microsoft.

Biotechnology 139

Biotechnology System Study Development 139

GeekWire

APRIL 15, 2021

Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, a theoretical physicist turned computational biologist who is the company’s chief scientific officer. Adaptive Biotechnologies Photo).

Biotechnology 91

Biotechnology Education Web Services Insurance 91

GeekWire

AUGUST 26, 2020

The Seattle biotech filed initial IPO paperwork Wednesday, a surprising move that would give the company additional capital to develop its therapies for brain diseases. Founded in 2011, Athira is in late-stage development for its lead therapeutic candidate called NDX-1017. Athira Pharma is aiming to go public.

Biotechnology 139

Biotechnology .Net Healthcare Development 139

GeekWire

MAY 24, 2021

New funding: Eliem Therapeutics raised $60 million to further development of its therapies for pain and depression. The pipeline: Founded in 2019, the company has two lead drug candidates in development : ETX-810 for chronic pain and ETX-155 for major depressive disorder, hormone-related mood disorders, and focal onset seizures.

Biotechnology 127

Biotechnology Pharmaceuticals Groups Development 127

GeekWire

APRIL 16, 2021

The category highlights pioneering health, life science, biotechnology or medical breakthroughs that hold great promise for bettering our lives or improving the healthcare system. Adaptive Biotechnologies. The company developed a first-of-its kind diagnostic tool called T-Detect COVID. Create your own user feedback survey.

Biotechnology 120

Biotechnology Virtualization Healthcare Artificial Intelligence 120